Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010827

CHIEF FINANCIAL OFFICER sold 14,000 shares at an average $24.72 ($346,149)

  • CHIEF FINANCIAL OFFICER acquired 14,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-04-11 Exercise or conversion : show line 1 in the form 10b5-1 +14,000 $2.48 $34,720 14,000 D
2024-04-11 Sale : show line 2 in the form 10b5-1 −3,777 $23.88 $90,179 10,223 D
2024-04-11 Sale : show line 3 in the form 10b5-1 −10,223 $25.04 $255,970 0 D
Open-market sales · 14,000 sh · avg $24.72 · $346,149

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-04-11 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −14,000 225,370 D
Loading xslF345X05/form4-04152024_110419.xml…